Valuation : AbbVie Inc.

Market Cap 440B 7,431B 378B 356B 325B 607B 41,833B 610B 4,222B 1,632B 21,312B 1,651B 1,615B 67,516B P/E 2026 *
31.9x
P/E 2027 * 23.7x
Enterprise Value 500B 8,453B 430B 405B 369B 691B 47,589B 694B 4,802B 1,856B 24,244B 1,878B 1,837B 76,806B EV / Sales 2026 *
7.4x
EV / Sales 2027 * 6.68x
Free-Float
95.71%
Yield 2026 *
2.76%
Yield 2027 * 2.9%
11:35am AbbVie Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 10:15 AM
09-08 BofA Securities Adjusts Price Target on AbbVie to $282 From $276 MT
09-03 AbbVie Announces Positive Topline Results From The Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma CI
09-03 AbbVie Inc. completed the acquisition of Apogee Therapeutics, Inc. from Fairmount Healthcare Fund II L.P managed by Fairmount Funds Management LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P managed by Venrock Management, LLC and other shareholders. CI
09-03 AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints MT
09-03 AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study DJ
09-03 AbbVie's blood cancer therapy lowers disease progression, death risk in trial RE
09-03 AbbVie's blood cancer drug meets late-stage trial goals RE
09-03 AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics MT
09-01 Global pharma companies that have publicly announced Trump drug pricing agreements RE
08-31 AbbVie Inc Receives Determination From Food And Drug Administration Regarding NAMENDA (Memantine Hydrochloride) Tablets 5 Mg And 10 Mg CI
08-27 AbbVie Seeks EU Approval for Subcutaneous Skyrizi Induction in Crohn's Disease MT
08-27 AbbVie Seeks European Regulatory Nod to Use Skyrizi as Subcutaneous Induction for Crohn's Disease Treatment MT
1 day-4.01%
1 week-3.10%
Current month-3.10%
1 month+1.55%
3 months+8.81%
6 months+2.86%
Current year+3.42%
1 week 4,250
Extreme 4250
4,250
1 month 4,250
Extreme 4250
4,515
Current year 3,420
Extreme 3420
4,635
1 year 3,420
Extreme 3420
4,635
3 years 2,375
Extreme 2375
4,635
5 years 2,115.61
Extreme 2115.61
4,635
10 years 1,062.02
Extreme 1062.02
4,635
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-4.01%-3.10% - - 440B
-0.24%-3.32%+49.41%+88.31% 1,002B
-0.22%-2.40%+51.79%+65.13% 649B
+0.50%-4.55%+18.72%+67.61% 440B
-0.80%-0.43%+28.92%+36.94% 346B
-0.13%-14.97%+9.41%+26.44% 263B
-1.90%-2.72%-2.72%+10.93% 250B
-0.17%-11.79%+39.53%+49.26% 213B
-1.06%-4.23%-14.70%-57.76% 201B
-0.54%-2.61%+25.87%+89.14% 182B
Average -0.85%-2.06%+22.91%+41.78% 393.74B
Weighted average by Cap. -0.77%-2.39%+31.96%+55.87%

Financials

2026 *2027 *
Net sales 67.58B 1,142B 58.16B 54.76B 49.9B 93.35B 6,431B 93.73B 649B 251B 3,276B 254B 248B 10,379B 73.52B 1,243B 63.26B 59.57B 54.28B 102B 6,996B 102B 706B 273B 3,564B 276B 270B 11,291B
Net income 13.86B 234B 11.93B 11.23B 10.23B 19.15B 1,319B 19.22B 133B 51.45B 672B 52.05B 50.92B 2,129B 18.91B 320B 16.28B 15.32B 13.96B 26.13B 1,800B 26.23B 182B 70.2B 917B 71.02B 69.48B 2,905B
Net Debt 60.49B 1,022B 52.05B 49.01B 44.66B 83.56B 5,756B 83.89B 581B 225B 2,932B 227B 222B 9,290B 51.66B 873B 44.45B 41.86B 38.14B 71.36B 4,916B 71.64B 496B 192B 2,504B 194B 190B 7,934B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-09-08 MX$4,250.00 -4.01% 17
26-09-02 MX$4,427.61 +0.95% 4,693
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
248.78USD
Average target price
276.79USD
Spread / Average Target
+11.26%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!